Cargando…
Can serum biomarkers predict the outcome of systemic immunosuppressive therapy in adult atopic dermatitis patients?
BACKGROUND: Atopic dermatitis (AD or eczema) is a most common chronic skin disease. Designing personalised treatment strategies for AD based on patient stratification is of high clinical relevance, given a considerable variation in the clinical phenotype and responses to treatments among patients. I...
Autores principales: | Hurault, G., Roekevisch, E., Schram, M. E., Szegedi, K., Kezic, S., Middelkamp‐Hup, M. A., Spuls, P. I., Tanaka, R. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060148/ https://www.ncbi.nlm.nih.gov/pubmed/35665204 http://dx.doi.org/10.1002/ski2.77 |
Ejemplares similares
-
Effect of immunosuppressive treatment on biomarkers in adult atopic dermatitis patients
por: Roekevisch, E., et al.
Publicado: (2020) -
Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series
por: Bosma, A. L., et al.
Publicado: (2021) -
Both children and adult patients with difficult‐to‐treat atopic dermatitis have high prevalences of concomitant allergic contact dermatitis and are frequently polysensitized
por: Boonstra, M., et al.
Publicado: (2018) -
Work ability and quality of working life in atopic dermatitis patients treated with dupilumab
por: Bosma, Angela L., et al.
Publicado: (2021) -
Classifying atopic dermatitis: a systematic review of phenotypes and associated characteristics
por: Bosma, A.L., et al.
Publicado: (2022)